Tumor Treating Fields for the Treatment of Brainstem Gliomas

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Sep 1, 2026 → Sep 1, 2027
See other at-risk trials from Emory University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 1, 2026 to Sep 1, 2027
    • Study completion pushed from May 1, 2027 to May 1, 2028
    • Site details revised at 2 of 3 sites
    • Eligibility criteria shortened, about 5 words
  2. Primary completion date: Sep 1, 2025 to Sep 1, 2026
    • Study completion date: May 1, 2026 to May 1, 2027
    • Site contacts updated at 3 of 3 sites
    v6
  3. Primary completion date: Nov 8, 2025 to Sep 1, 2025
    • Study completion date: Nov 8, 2025 to May 1, 2026
    • Site contacts updated at 3 of 3 sites
    v5
  4. Primary and study completion dates: Mar 1, 2024 to Nov 8, 2025v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2022 to May 11, 2022
    • Site details revised at 3 of 3 sites
    • Collaborators: 2 to 1
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Emory University
377 trials monitored
See 20 trials at risk
Glioma
1,253 trials monitored
See 90 trials at risk
This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with cancer cell division. TTFields may prevent growth or decrease size of gliomas in patients
Trial Details
NCT Number NCT05310448
Lead Sponsor Emory University
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Glioma
Related terms Glioma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov